Washington, DC – Feb 18, 2004 – Prestwick Pharmaceuticals, Inc. announced that Robert Whitehead, President and CEO of Prestwick Pharmaceuticals, Inc., will present at the Smith Barney 4th Annual Specialty Pharmaceuticals Conference, February 24, 2004 at 11:50 a.m. (Eastern) at the Marriott East Side Hotel in New York City, Stuyvesant Ballroom.

About Prestwick Pharmaceuticals
Prestwick Pharmaceuticals, Inc. is an emerging Specialty Biopharmaceutical company that focuses on treatments for Central Nervous System (CNS) disorders. Prestwick has multiple late-stage product candidates for CNS disorders in clinical development. The company’s lead product, Tetrabenazine, has been approved in Europe, Canada, and Australia for a series of disabling hyperkinetic movement disorders. Tetrabenazine is currently undergoing pivotal Phase III clinical testing in the U.S. and Prestwick plans to file an NDA in 2004. Prestwick plans to commercialize Tetrabenazine in the U.S. as soon as FDA approval is obtained. For more information on Prestwick Pharmaceuticals, Inc., visit www.prestwickpharma.com.